Trial reportCerebellum (London, England)2026
Efficacy of Cerebellar Transcranial Direct Current Stimulation in Degenerative Ataxia. A Sham-Controlled Clinical and Quantitative Analysis.
Trial report in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07250321 (Efficacy of Cerebellar Transcranial Direct Current Stimulation in Degenerative Ataxia. A Sham-controlled Clinical and Quantitative Analysis.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Cerebellar Transcranial Direct Current Stimulation in Degenerative Ataxia. A Sham-controlled Clinical and Quantitative Analysis.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Neurodegenerative ataxias represent a heterogeneous group of disorders lacking effective treatments. This double-blind, sham-controlled study investigated the therapeutic potential of cerebellar transcranial Direct Current Stimulation (tDCS) in degenerative ataxia. Sixteen patients were randomized to receive either real or sham tDCS (10 sessions). Clinical evaluation, quantitative assessment of gait and upper limb function (through the "hand-to-mouth" task) and EEG were performed before and after treatment. Clinical outcome tools included the Modified International Cooperative Ataxia Rating Scale (MICARS), the Scale for the Assessment and Rating of Ataxia (SARA) and the Robertson dysarthria profile to rate ataxic and dysarthric symptoms. Quantitative kinematic assessment of upper and lower limb motor function was carried out by means of optical motion capture system. At last, resting state electroencephalography (EEG) enabled evaluation of cortical oscillatory changes. The primary outcomes were change from baseline in SARA and MICARS total scores; secondary outcomes included changes in Robertson dysarthria profile score, spatiotemporal gait and hand‑to‑mouth kinematics and cortical beta/gamma power on resting state EEG. Both real and sham tDCS groups showed improvements in ataxic and dysarthric symptoms, but real tDCS induced greater benefits in posture, gait (MICARS), and upper-limb coordination (SARA) subscales. Although statistical significance was not reached for main gait parameters, a higher proportion of patients receiving real tDCS demonstrated clinically meaningful gains in gait speed and step width. In contrast, hand-to-mouth parameters remained unchanged. EEG showed increases in central/parietal beta and low‑gamma power after active but not sham stimulation, supporting neuromodulatory effects on the cerebello-thalamo-cortical network. Overall, these data support a therapeutic potential of cerebellar tDCS in improving symptoms in degenerative ataxia of different aetiology and contribute to elucidate the mechanisms underlying these effects. ClinicalTrials.gov registration: NCT07250321 (registered 2025-11-18).
Indexed as
Identifiers
41533249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.